Cargando…

Molecular imaging biomarkers for cell-based immunotherapies

While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Haris, Mohammad, Bagga, Puneet, Hariharan, Hari, McGettigan-Croce, Bevin, Johnson, Laura A., Reddy, Ravinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477274/
https://www.ncbi.nlm.nih.gov/pubmed/28629457
http://dx.doi.org/10.1186/s12967-017-1240-6
_version_ 1783244757852487680
author Haris, Mohammad
Bagga, Puneet
Hariharan, Hari
McGettigan-Croce, Bevin
Johnson, Laura A.
Reddy, Ravinder
author_facet Haris, Mohammad
Bagga, Puneet
Hariharan, Hari
McGettigan-Croce, Bevin
Johnson, Laura A.
Reddy, Ravinder
author_sort Haris, Mohammad
collection PubMed
description While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current arsenal of cancer treatments; surgery, radiation and chemotherapy, and increasing the therapeutic options for cancer patients. Despite these advances, issues associated with these therapies include that not all patients respond to these therapies, and some patients who respond experience varying degrees of toxicities. One of the major issues affecting immunotherapy is the inability to evaluate trafficking of activated T-cells into sites of tumor. The current diagnostic imaging based on conventional anatomic imaging, which is the mainstay to monitor response to cytotoxic chemotherapy or radiation, is not adequate to assess initial response to immunotherapy or disease evolution. Patients’ prognosis by histological analysis has limited use in regards to immunotherapy. Thus, there is a crucial need for noninvasive biomarkers for screening patients that show long term response to therapy. Here, we provide a brief account of emerging molecular magnetic resonance imaging biomarkers that have potential to exploit the metabolism and metabolic products of activated T cells.
format Online
Article
Text
id pubmed-5477274
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54772742017-06-23 Molecular imaging biomarkers for cell-based immunotherapies Haris, Mohammad Bagga, Puneet Hariharan, Hari McGettigan-Croce, Bevin Johnson, Laura A. Reddy, Ravinder J Transl Med Review While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of cancers. These treatments are adding to the current arsenal of cancer treatments; surgery, radiation and chemotherapy, and increasing the therapeutic options for cancer patients. Despite these advances, issues associated with these therapies include that not all patients respond to these therapies, and some patients who respond experience varying degrees of toxicities. One of the major issues affecting immunotherapy is the inability to evaluate trafficking of activated T-cells into sites of tumor. The current diagnostic imaging based on conventional anatomic imaging, which is the mainstay to monitor response to cytotoxic chemotherapy or radiation, is not adequate to assess initial response to immunotherapy or disease evolution. Patients’ prognosis by histological analysis has limited use in regards to immunotherapy. Thus, there is a crucial need for noninvasive biomarkers for screening patients that show long term response to therapy. Here, we provide a brief account of emerging molecular magnetic resonance imaging biomarkers that have potential to exploit the metabolism and metabolic products of activated T cells. BioMed Central 2017-06-19 /pmc/articles/PMC5477274/ /pubmed/28629457 http://dx.doi.org/10.1186/s12967-017-1240-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Haris, Mohammad
Bagga, Puneet
Hariharan, Hari
McGettigan-Croce, Bevin
Johnson, Laura A.
Reddy, Ravinder
Molecular imaging biomarkers for cell-based immunotherapies
title Molecular imaging biomarkers for cell-based immunotherapies
title_full Molecular imaging biomarkers for cell-based immunotherapies
title_fullStr Molecular imaging biomarkers for cell-based immunotherapies
title_full_unstemmed Molecular imaging biomarkers for cell-based immunotherapies
title_short Molecular imaging biomarkers for cell-based immunotherapies
title_sort molecular imaging biomarkers for cell-based immunotherapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477274/
https://www.ncbi.nlm.nih.gov/pubmed/28629457
http://dx.doi.org/10.1186/s12967-017-1240-6
work_keys_str_mv AT harismohammad molecularimagingbiomarkersforcellbasedimmunotherapies
AT baggapuneet molecularimagingbiomarkersforcellbasedimmunotherapies
AT hariharanhari molecularimagingbiomarkersforcellbasedimmunotherapies
AT mcgettigancrocebevin molecularimagingbiomarkersforcellbasedimmunotherapies
AT johnsonlauraa molecularimagingbiomarkersforcellbasedimmunotherapies
AT reddyravinder molecularimagingbiomarkersforcellbasedimmunotherapies